Cellebrite DI (CLBT) | Financial Analysis & Statements
Cellebrite DI Ltd. Mid-cap Technology
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
128.8M
Gross Profit
109.1M
84.71%
Operating Income
20.8M
16.15%
Net Income
21.3M
16.50%
EPS (Diluted)
$0.08
Balance Sheet Metrics
Total Assets
938.9M
Total Liabilities
454.5M
Shareholders Equity
484.3M
Debt to Equity
0.94
Cash Flow Metrics
Operating Cash Flow
75.3M
Free Cash Flow
82.9M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Cellebrite DI Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 475.7M | 401.2M | 325.1M | 270.7M | 246.2M |
| Cost of Goods Sold | 75.2M | 62.6M | 53.2M | 50.7M | 42.6M |
| Gross Profit | 400.5M | 338.6M | 271.9M | 219.9M | 203.7M |
| Gross Margin % | 84.2% | 84.4% | 83.6% | 81.3% | 82.7% |
| Operating Expenses | |||||
| Research & Development | 113.9M | 98.4M | 84.4M | 80.6M | 65.5M |
| Selling, General & Administrative | 220.1M | 183.3M | 154.3M | 138.2M | 124.3M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 334.0M | 281.7M | 238.6M | 218.9M | 189.9M |
| Operating Income | 66.5M | 56.9M | 33.2M | 1.0M | 13.8M |
| Operating Margin % | 14.0% | 14.2% | 10.2% | 0.4% | 5.6% |
| Non-Operating Items | |||||
| Interest Income | 23.9M | 18.2M | 8.9M | 1.6M | 847.0K |
| Interest Expense | 523.0K | 29.0K | 141.0K | 149.0K | 153.0K |
| Other Non-Operating Income | 737.0K | -1.3M | 206.0K | 845.0K | -194.0K |
| Pre-tax Income | 90.7M | -276.0M | -75.6M | 120.8M | 82.3M |
| Income Tax | 12.4M | 7.0M | 5.5M | -45.0K | 10.9M |
| Effective Tax Rate % | 13.6% | 0.0% | 0.0% | -0.0% | 13.3% |
| Net Income | 78.3M | -283.0M | -81.1M | 120.8M | 71.4M |
| Net Margin % | 16.5% | -70.5% | -24.9% | 44.6% | 29.0% |
| Key Metrics | |||||
| EBITDA | 102.3M | -264.0M | -65.6M | 129.3M | 89.7M |
| EPS (Basic) | $0.32 | $-1.35 | $-0.43 | $0.64 | $0.49 |
| EPS (Diluted) | $0.31 | $-1.35 | $-0.43 | $0.59 | $0.44 |
| Basic Shares Outstanding | 241626316 | 209471827 | 190154549 | 182693375 | 144002394 |
| Diluted Shares Outstanding | 241626316 | 209471827 | 190154549 | 182693375 | 144002394 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Cellebrite DI Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 124.5M | 191.7M | 189.5M | 87.6M | 146.0M |
| Short-term Investments | 312.6M | 255.6M | 113.4M | 96.0M | 35.6M |
| Accounts Receivable | 105.0M | 82.4M | 77.3M | 78.8M | 67.5M |
| Inventory | 7.6M | 8.9M | 9.9M | 10.2M | 6.5M |
| Other Current Assets | 4.5M | 12.4M | 16.9M | 8.5M | 3.1M |
| Total Current Assets | 575.8M | 567.6M | 422.1M | 295.9M | 273.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 16.9M | 11.2M | 14.8M | 16.2M | 526.0K |
| Goodwill | 320.6M | 68.7M | 64.3M | 64.9M | 64.9M |
| Intangible Assets | 81.5M | 11.3M | 10.6M | 11.3M | 11.2M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 25.5M | 18.8M | 14.4M | 14.2M | 11.8M |
| Total Non-Current Assets | 363.0M | 123.0M | 110.8M | 107.4M | 66.6M |
| Total Assets | 938.9M | 690.6M | 532.9M | 403.3M | 339.8M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 16.8M | 11.1M | 8.3M | 4.6M | 9.5M |
| Short-term Debt | 4.0M | 4.1M | 5.0M | 5.0M | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 369.7M | 295.5M | 253.8M | 207.8M | 186.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 18.7M | 6.8M | 9.2M | 10.4M | 0 |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 16.7M | 7.0M | 134.5M | 49.1M | 133.7M |
| Total Non-Current Liabilities | 84.9M | 59.0M | 244.8M | 121.7M | 226.6M |
| Total Liabilities | 454.5M | 354.5M | 498.7M | 329.4M | 413.1M |
| Equity | |||||
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -86.5M | -164.9M | 118.1M | 199.2M | 78.4M |
| Treasury Stock | 85.0K | 85.0K | 85.0K | 85.0K | 85.0K |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 484.3M | 336.0M | 34.2M | 73.9M | -73.3M |
| Key Metrics | |||||
| Total Debt | 22.7M | 11.0M | 14.1M | 15.4M | 0 |
| Working Capital | 206.2M | 272.1M | 168.3M | 88.2M | 86.6M |
Balance Sheet Composition
Cellebrite DI Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 78.3M | -283.0M | -81.1M | 120.8M | 71.4M |
| Depreciation & Amortization | 11.9M | 10.6M | 10.0M | 9.2M | 7.0M |
| Stock-Based Compensation | 44.9M | 30.6M | 19.0M | 13.7M | 6.5M |
| Working Capital Changes | 36.7M | 21.3M | 47.0M | 11.7M | 23.9M |
| Operating Cash Flow | 163.7M | 3.6M | 77.5M | 72.0M | 51.2M |
| Investing Activities | |||||
| Capital Expenditures | -13.2M | -8.6M | -5.2M | -6.9M | -5.1M |
| Acquisitions | -147.5M | -2.7M | 0 | 0 | -20.0M |
| Investment Purchases | -508.2M | -334.8M | -144.3M | -165.4M | -21.0M |
| Investment Sales | 400.7M | 198.7M | 129.7M | 83.2M | 94.3M |
| Investing Cash Flow | -268.2M | -147.4M | -19.9M | -89.0M | 48.2M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | 0 | 0 |
| Dividends Paid | - | - | 0 | 0 | -100.0M |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | - | -11.0K | 0 | 0 | -70.7M |
| Free Cash Flow | 160.3M | 121.6M | 94.1M | 11.5M | 27.9M |
| Net Change in Cash | -104.5M | -143.8M | 57.7M | -17.1M | 28.7M |
Cash Flow Trend
Cellebrite DI Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
42.90
Forward P/E
21.80
Price to Book
6.83
Price to Sales
6.97
PEG Ratio
3.43
Profitability Ratios
Profit Margin
16.47%
Operating Margin
16.15%
Return on Equity
19.10%
Return on Assets
5.10%
Financial Health
Current Ratio
1.56
Debt to Equity
4.68
Beta
1.28
Per Share Data
EPS (TTM)
$0.31
Book Value per Share
$1.95
Revenue per Share
$1.97
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| CLBT | 3.2B | 42.90 | 6.83 | 19.10% | 16.47% | 4.68 |
| Microsoft | 3.1T | 26.56 | 8.06 | 34.39% | 39.04% | 31.54 |
| Oracle | 498.4B | 31.65 | 15.11 | 57.57% | 25.30% | 415.27 |
| DigitalOcean | 9.9B | 37.78 | -304.26 | -903.67% | 28.76% | -59.30 |
| Nutanix | 9.3B | 37.40 | -11.11 | -27.12% | 9.95% | -1.86 |
| Informatica | 7.6B | 826.33 | 3.12 | 0.43% | 0.62% | 75.61 |
Financial data is updated regularly. All figures are in the company's reporting currency.






